[{"orgOrder":0,"company":"Ludwig Enterprises","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Ludwig Enterprises","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ludwig Enterprises \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ludwig Enterprises \/ Inapplicable"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amino Acids Mixture","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"APR Applied Pharma Research \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"APR Applied Pharma Research \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for FREAMINE HBC 6.9%

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.

                          Product Name : NuGenea

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 25, 2023

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : PKU GOLIKE® - a next generation medical phenylalanine-free food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria (PKU).

                          Product Name : PKU GOLIKE

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 10, 2022

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches.

                          Product Name : PKU Golike

                          Product Type : Other Small Molecule

                          Upfront Cash : $23.3 million

                          June 29, 2021

                          Lead Product(s) : Amino Acids Mixture,Minerals,Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Relief Therapeutics

                          Deal Size : $72.2 million

                          Deal Type : Acquisition

                          blank